See Clearly Vision Group, 8138 Watson Street, McLean, VA, 22102, USA,
Adv Ther. 2013 Oct;30(10):907-23. doi: 10.1007/s12325-013-0059-7. Epub 2013 Oct 18.
We aimed to evaluate the safety and efficacy of loteprednol etabonate (LE) gel 0.5% compared with vehicle in the treatment of postoperative inflammation and pain following cataract surgery, using the integrated analysis of data from two identical, prospective, multicenter, randomized, double-masked, parallel-group, vehicle-controlled trials.
Patients with anterior chamber cell (ACC) inflammation ≥ grade 2 (6-15 cells) 1 day post-surgery were randomized to receive 1 or 2 drops of LE gel 0.5% or vehicle 4 times per day instilled in the study eye for 14 days. Primary outcome measures included the proportion of patients with complete resolution of ACC and grade 0 (no) pain on postoperative Day 8. Safety endpoints included adverse events (AEs), changes from baseline in intraocular pressure (IOP) and visual acuity (VA), biomicroscopy, and funduscopy findings. Gel comfort was graded by patients according to drop sensation.
The intent-to-treat population included 813 patients (409 LE gel 0.5% and 404 vehicle). At postoperative Day 8, 30.8% and 15.1% of patients randomized to LE gel 0.5% or vehicle, respectively, had complete resolution of ACC, while 74.3% and 43.8% of patients, respectively, had grade 0 pain (P < 0.001 for both). Tolerability assessments for ocular itching, photophobia, and tearing favored LE gel 0.5% compared with vehicle at different time points beginning at Day 3. Two patients in the LE gel 0.5% group and 1 patient in the vehicle group exhibited a transient treatment-emergent increase in IOP ≥ 10 mmHg. Treatment-related AEs were generally mild to moderate and occurred less frequently with LE gel 0.5% than with vehicle. Reports of treatment-related blurred vision were rare (n = 2, vehicle).
LE gel 0.5% was efficacious and well tolerated in the treatment of postoperative pain and inflammation following ocular surgery, with minimal risk of IOP elevation.
我们旨在评估洛度沙胺(LE)凝胶 0.5%与载体在白内障手术后炎症和疼痛治疗中的安全性和有效性,使用来自两项相同的、前瞻性的、多中心的、随机的、双盲的、平行组的、载体对照试验的数据的综合分析。
术后第 1 天前房细胞(ACC)炎症≥2 级(6-15 个细胞)的患者被随机分配接受 1 或 2 滴 LE 凝胶 0.5%或载体,每天 4 次,在研究眼中滴注 14 天。主要疗效评估指标包括术后第 8 天 ACC 完全缓解和 0 级(无)疼痛的患者比例。安全性终点包括不良事件(AE)、眼压(IOP)和视力(VA)、生物显微镜和眼底镜检查结果的基线变化。患者根据滴注感觉对凝胶舒适度进行分级。
意向治疗人群包括 813 例患者(LE 凝胶 0.5%组 409 例,载体组 404 例)。术后第 8 天,分别有 30.8%和 15.1%随机分配到 LE 凝胶 0.5%或载体的患者 ACC 完全缓解,而分别有 74.3%和 43.8%的患者疼痛程度为 0 级(均 P<0.001)。从第 3 天开始,不同时间点,眼部瘙痒、畏光和流泪的耐受性评估均有利于 LE 凝胶 0.5%,而不利于载体。LE 凝胶 0.5%组有 2 例患者和载体组有 1 例患者出现短暂的治疗性眼压升高≥10mmHg。治疗相关的 AE 通常为轻度至中度,且 LE 凝胶 0.5%组发生频率低于载体组。治疗相关的视力模糊报告很少见(n=2,载体)。
LE 凝胶 0.5%在治疗眼部手术后的疼痛和炎症方面有效且耐受性良好,眼压升高的风险最小。